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be seen as blocking access. As the marginal cost (MC) of a new product is lower than 
the charged price there is a well-known waste. One option is to establish a two-part 
pricing model with a “subscription” price plus a usage price close to MC. The objec-
tive of this paper is to provide an economic analysis based on theories and concepts 
from microeconomics and industrial organization of two-part pricing in the market 
for patent protected medicines (PPM). Methods: The situation will be analyzed from 
a game theoretical and an empirical perspective. The starting point is the Swedish 
Health Care system with focus on oncology. A two-part pricing contractual arrange-
ment will also be discussed for some other EU countries. Results: Demand side 
consists of a publicly funded local buyer who represents a large number of potential 
users. This often leads to a bargaining solution where price is below the one set by a 
standard monopoly. A two-part pricing - where the buyer pays a substantial fixed-fee 
to get access to the PPM and a per unit price equal to marginal cost – may increase 
efficiency. However, numerous issues need to be taken into account when consider-
ing introducing two-part pricing, for example uncertainty and risk, the operation on 
many markets, free-riders and reselling. ConClusions: Quantities are unlikely to 
be efficient with the current pricing model in the Swedish oncological market. A two-
part pricing is likely to increase the efficiency in such markets but is also associated 
with some serious challenges.
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objeCtive: To introduce the development of Chinese pediatric medicine, and based 
on foreign experiences propose some measures that China should take immediately 
for improving the access to pediatric medicine and promote Chinese innovation 
for pediatric medicine. Methods: Data were mainly obtained from the National 
Bureau of Statistics of China, the open Chinese government documents and some 
published papers. Apply descriptive statistics and comparison to summarize poli-
cies’ lacks and propose some suggestions. Results: In 2013, there are 220 million 
Children under 14 years old who account for 16.4% of total Chinese population. In 
the 2009 National Reimbursement Drug List, the number of pediatric medicines 
is about 60 and accounts for 1.52% in all 3500 drugs, 80% of which does not have 
usage information of “exclusive pediatric medicine”, 90% of which does not have 
pediatric formulation. Adverse reaction rate of pediatric medicine is 12.9%, which is 
obviously higher than adult medicine. ConClusions: China should immediately 
take some incentive measures to encourage the innovation of pediatric medicines 
based on foreign experiences
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Incorporating the patient perspective on the value of medicines into health tech-
nology assessments (HTA) is becoming increasingly important as acknowledged 
by several prominent HTA agencies. NICE (UK) has employed several measures, 
including a Citizen’s Council. Canada, particularly in the area of oncology, has a 
formalized process through which patient input on drug reviews and feedback 
on recommendations is obtained to ensure patients’ experiences (both good and 
bad) of living with cancer and undergoing treatment are routinely considered. 
In Australia, there is a consumer representative on the Pharmaceutical Benefits 
Advisory Committee (PBAC) and patients have the opportunity to provide written 
input during the assessment process, although the process of how PBAC consider 
and incorporate this information into their decision is not transparent. There is a 
need for a more formalized framework for eliciting meaningful patient input and 
a more transparent process for how that input is incorporated into the decision 
making process. This research seeks to outline a novel methodological approach 
to elicit and quantify patient values in a systematic way for the purpose of treat-
ment evaluation (Patient Value Mapping). The focus of this research is Chronic 
Lymphocytic Leukemia (CLL) and involves patient participation in multiple research 
stages. Stage 1 involves conducting exploratory qualitative interviews and semi-
structured quantitative surveys to gauge how patients view treatments and what 
outcomes are most important to them. Stage 2 quantifies the insights from stage 
1 using discrete choice based methods, including measuring the relative weight-
ings of importance on each of the outcomes and the associated willingness to pay. 
Current and proposed treatments are entered into the resulting model and scored 
based on how well they align with patient values and expectations. The results of 
this analysis could be incorporated into the HTA evaluation process and used to 
guide decisions around the value of new medicines.
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objeCtives: Traditionally, business-related projects are either executed by employ-
ees within an organization or outsourced to external vendors. Crowdsourcing, on 
the other hand, allows sponsors to leverage the Internet to draw upon the skills 
and experiences of the public in open forums to generate new ideas or deliverables. 
Crowdsourcing for healthcare technology innovation has become increasingly popu-
lar; however, the type of stakeholders involved and healthcare technologies sought 
are not well understood. The aim of this study is to characterize crowdsourcing 
competitions focused on healthcare technology innovation. Methods: Information 
was gathered from the Health 2.0 Developer Challenge website, a leading online 
competition platform where complex healthcare challenges are crowdsourced by 
sponsoring agencies to teams of developers. Completed challenges listed on the 
platform from January 2007-October 2014 were identified. For each challenge, total 
prize money, stakeholder type, and challenge theme were examined. Results: 
A total of 57 challenges were identified with $3.31 million awarded as total prize 
money (mean= $75,250; median= $40,000; max= $750,000). Government agencies 
sponsored the majority of challenges (46%), followed by non-profit (37%) and 
for-profit (25%) organizations. Four (7%) challenges were sponsored by pharma-
ceutical companies and accounted for 14% of total prize money (mean= $117,500; 
median= $150,000; max= $160,000). The five most common challenge themes iden-
tified were data management (25%), enhanced decision making (16%), communi-
cation barrier (14%), health education (14%), wellness/tracking (11%), and disease 
prevention/screening (11%). ConClusions: Although government agencies were 
the most common sponsors of crowdsourced healthcare technology challenges, 
pharmaceutical companies offered the highest mean monetary awards. Data man-
agement solutions (e.g. electronic health record applications) were the most fre-
quently solicited theme among all challenges. Crowdsourcing shows promise as a 
source of innovative healthcare technology solutions; however, more research is 
needed to explore the viability of such solutions.
PHP182
anaLysIs oF etHIcaL tHeorIes and PrIncIPLes embedded In HoLIstIc 
mcda: a PrImer to etHIcs-based aPPraIsaL oF vaLue In HeaLtHcare
Goetghebeur M.M.1, Wagner M.1, Bond K.2, Hofmann B.3
1LASER Analytica, Montreal, QC, Canada, 2Canadian Agency for Drugs and Technologies in 
Health, Ottawa, ON, Canada, 3Institute of Health and Society, Oslo, Norway
objeCtives: MCDA provide innovative approaches to measure the value of inter-
ventions and support decision making. A broad range of criteria are used to integrate 
big data and reflect the various constraints under which healthcare decisions are 
made. The objective of this study was to analyze the ethical theories and principles 
embedded in the criteria of holistic MCDA. Methods: EVIDEM was selected as a 
holistic framework aiming at defining value, or goodness, of healthcare interven-
tions, in its widest sense (axiology), i.e., encompassing their effects on health of 
patients, populations and healthcare systems. Each criterion of the framework was 
analyzed regarding its ethical background theories, inherent norms, values, and 
associated principles, and ethical implications. A broad range of ethical theories and 
positions were considered including virtue ethics, deontology, consequentialism, 
utilitarianism, theory of justice, human rights, and principlism. Results: Criteria 
related to healthcare intervention outcomes (“Effectiveness”, “Safety”, “Patient-
reported outcomes”, Type of benefit) are expressed in the Hippocratic Oath and 
rooted in deontology (imperative to help), principlism (autonomy, beneficence, non-
maleficence), and also in consequentialism. “Disease severity“, “Unmet needs” and 
“Priorities” are related to the theory of justice to prioritize those who are worst 
off, but also to deontology and virtue ethics. “Size of population” is rooted in utili-
tarianism pursuing the greatest good for the greatest number. Economic criteria 
as an inherent part of value appraisal ensure wise use of resources (virtue ethics 
[practical wisdom]) to maximize health under limited resources based on social 
responsibility (utilitarianism). “Affordability and Opportunity costs” and “System 
capacity and appropriate use” are related to consequentialism while “Political/his-
torical/cultural” and “Stakeholders pressure/barriers” are rooted in virtue ethics and 
human rights. ConClusion: Holistic MCDA systematically incorporates a broad 
range of ethical perspectives, norms, values and principles, and as such is a norma-
tive approach for prioritizing healthcare interventions that optimize patients’ and 
healthcare systems health.
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objeCtives: Electronic Healthcare databases and use of machine learning algo-
rithms has created opportunities for rapid learning. However, the indiscriminate 
application of machine learning algorithms to non-experimental healthcare 
databases may result in incorrect inferences about possible treatment benefits. 
This paper compares results from large healthcare databases produced by sta-
tistical, machine learning, and hybrid methods to emphasize the importance 
of controlling for known biases in healthcare databases and machine learning 
algorithms. Methods: MS patient cases were selected from an EMR database 
that met the following criteria: Must be on an MS therapy for at least one year 
and diagnosed with at least one co morbidity prior to and during the treatment 
period. Co morbidity improvements are measured by changes in specific lab val-
ues measured prior to and during treatment. To facilitate method comparison, a 
binary variable was constructed to measure improvements in co morbidities expe-
rienced during MS therapy. Treatment groups were defined by specific MS thera-
pies and compared to control groups treated with alternative therapies during 
the observation period. Propensity scores were used with all methods. Statistical 
and machine learning algorithms were compared to a hybrid algorithm, SIDES, 
originally designed for subpopulation analysis in RCT’s while controlling for multi-
plicity bias (Lipkovich et al. 2011). Results: Initial analyses identified differences 
in predictors of co mobidity improvements. The presentation will cover specific 
comparisons between different methods, highlight similarities and differences 
in findings and provide rationales for divergent results. ConClusion: Machine 
learning methods (such as SIDES) designed for use in RCTs can be adapted for use 
with large healthcare databases to accelerate learning and discovery while also 
including protections against known sources of bias in healthcare data (treat-
ment selection) and machine learning methods (multiplicity) that can lead to 
incorrect inferences.
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Financial constraints versus public desire for more-generous healthcare create a 
difficult dilemma for countries globally. As each market strives to manage its pre-
scription drug market, highly specific market access requirements and challenges 
abound for drugmakers. Innovative developers must engage with payers much 
earlier in the product development cycle in order to optimize trial design to satisfy 
specific MA and payer requirements on demonstrating innovation (e.g. selecting 
the appropriate comparator, targeting the correct/local patient population, gather-
ing the most compelling head-to-head). By exploring how pricing and reimburse-
ment (P&R) decisions are made in many major and developing markets around the 
world, we have developed a Country Archetypes model that identifies similarities 
among payer requirements, and, vitally, determines where product value messaging 
can be leveraged to optimize market access strategy. Data on payer type and drug 
review processes, payer fragmentation, percentage of individuals covered by a health 
insurance system, size of the pharmaceutical market, percentage of government 
and individuals in healthcare spending, and use as a reference country for other 
nations were collected for 27 of the largest pharmaceutical markets in the world. 
Considerations around free pricing, health technology assessment, and review of 
pharmacoeconomic and outcomes research data rules were made, and further seg-
mentations on decision impact, size of reimbursable market, out-of-pocket costs, 
role of health insurance and market fragmentation applied. Ultimately, from the 
27 nations examined, six groups emerged, each comprising countries with com-
monalities across all measures, albeit distinct profiles that affect P&R: Accountants, 
Pragmatists, Evidence seekers, Deal-makers, Ceiling setters, and Independents. 
Our Country Archetype model is intended to help multinational pharmaceuti-
cal companies prepare for local reimbursement evaluations, and pinpoint where 
decision-makers can be found. With classifications based on the most important 
set of reimbursement criteria necessary to attain favorable access in each market, 
the keys to access can be found and turned.
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Kazakhstan is an upper-middle-income country with per capita GDP of nearly US$13 
thousand in 2013. Kazakh’s public healthcare system – UNHS (Unified National Health 
System) – aims to deliver healthcare coverage to the whole population. Despite this 
objective, only two thirds of interventions (on average) in UNHS were fully covered by 
public funding, while the remaining were funded by patients through either private 
health schemes or out-of pocket payments. Finding better ways to manage the use 
and cost of health technology is a high priority for Kazakh policy makers. As health 
policy makers face increasing pressure from the public to make explicit determina-
tions about how and which technologies will be covered within the state guaranteed 
benefits package, the profile and scrutiny of HTA activity has, consequently, also 
increased. Even though there has been a rapid growth of HTA activities, HTA has not 
been developed as much as expected. There are several possible reasons why the MoH 
did not develop the strategy adopting HTA. First, comprehensive evaluation through 
HTA would make clear the failure of health policy previously implemented. Second, 
the MoH still relied on the traditional consensus method based on opinion or experi-
ence, which favors incremental and marginal changes, rather than a drastic reform. 
Third, there has been a power game of politics between innovative and conservative 
groups in the MoH. The Kazakh health care system needs HTA to be constructive to 
enable decision makers to make informed decisions with regard to the adoption of 
health technology. The development and promotion of clear criteria for selection of 
HTA topics is, therefore, essential to promote the efficient use of HTA information for 
decision making with respect to setting ultimate goals for HTA.
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Despite the average Indian patient becoming more knowledgeable with regards to 
his/her health, disease and treatment options, many Indian physicians still depend 
heavily on disease-related outcome measures to take health-care related decisions, 
and give minimal importance to patient-reported outcomes (PROs) pertaining to the 
effect of the healthcare interventions on the patient’s well-being. This trend is also 
seen in clinical trials (CTs) in India where PROs, if used, are only secondary to disease-
related outcomes. As on today, there are no commendable patient-centered outcome 
researches (PCORs) happening in India. With the arrival of PCOR Institute (PCORI) in 
the US, PROs are now getting the attention that they deserve; however, in India the 
concept is yet to catch up. PROs have a significant role in CTs, such as determination 
of patient eligibility, determination of patient compliance, as a study endpoint, deter-
mination of health-related quality of life (HRQoL), and assessing economic burden and 
indirect impact of disease and treatment. Implementation of regular PROs assessment 
in clinical trials can help in determining the negative effects of therapy, comparing 
two standard therapies having similar survival outcomes, finding out whether a new 
therapy is preferable to standard therapy, determining whether a therapeutic regimen 
is better than supportive care only, when survival time is short, and making the com-
munication easier in clinical practice. Improved design and proper implementation 
of PROs in clinical trials (CTs) are necessary to provide high quality evidence to syn-
thesize clinical practice guidelines. Implementation of PROs in CTs should be made 
mandatory for pharmaceutical companies to prove their label claims, especially in 
a country like India where the generic market is strong and widespread. Also, data 
obtained from PROs in CTs should be made the source document for making health-
related decisions at all levels in India.
PHP187
tHe PILLars oF cost-eFFectIveness: a PractIcaL guIdeLIne For new 
tecHnoLogy cost-eFFectIve decIsIon-makIng
CalderÓn M.R.
Novartis Pharmaceuticals, Guatemala, Guatemala
bACKGRound: The critical importance and use of health technology assessment 
in health care decisions towards improved health is practically nonexistent in 
many Central American and Caribbean countries. A culture with a health eco-
nomics mindset that enhances access to new technologies is needed, one that 
increases the knowledge and application of economic evaluation amongst health 
stakeholders to make cost-effective decisions that improve health. objeCtives: In 
general, to find new ways to make new drugs and technologies available to patients, 
healthcare providers, governments and society as a whole. Specifically, to develop 
a practical guideline for the pharmaceutical and healthcare industries to make 
new technologies available to patients in resource-limited settings. Methods: A 
needs assessment was conducted amongst key internal (pharmaceutical industry) 
and external stakeholders (public, private and non-profit institutions) in Central 
America and the Caribbean to gain insight into their decision-making basis and 
behaviors regarding new technology acquisition. A literature review of lessons 
learned and best practices around the world complemented the information col-
lected from local stakeholders. Results: A pivotal concept was created and coined 
as Pillars of Cost-Effectiveness. This concept advocates for three types of “effective-
ness” comprising each three types of strategic considerations as follows: 1. Clinical 
Effectiveness: safety, efficacy and quality, 2. Medical Access Effectiveness: value-
added services, impact information dissemination and managed-entry agreements, 
and 3. Economic Effectiveness: burden of disease data, cost-effectiveness evidence 
and budget impact analysis. ConClusion: The Pillars of Cost-Effectiveness may 
serve as the “New Technology Cost-Effectiveness Checklist” to make evidence-based 
decisions in resource-limited settings. In turn, it may become the tool to assess 
and assure the universal goals of patients, providers, payers and policy-makers to 
(1) get the best drug and technology quality at the lowest cost and with reasonable 
access, and (2) enhance healthcare partnerships and solutions towards improved 
individual and population health outcomes.
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bACKGRound: Cancer is an increasing problem in developing countries. It ranks 
as the fourth leading cause of death in the eastern Mediterranean region and is 
one of the leading causes of death in the world. Although, in developing countries, 
incidence of cancer is still below that in the developed ones, they are expected to 
experience an increase in the burden of cancer, which if added to the more limited 
resources available, requires immediate intervention. Multiple projects had been 
initiated, but facing technical and other problems related to resources and equity 
leads them to be ineffective and inefficient. Objectives: Developing the nucleus for 
numerous Oncology Hospital-Based HTA (HB HTA) units as a tool for evidence based 
decision making and better utilization of resources to reach for a highly performing 
healthcare system. Methods/Responsibilities: Decentralized HB HTA emerges 
from the need to take tailored healthcare decisions in a short period of time. These 
decisions should make use of local intrinsic data, providing solutions that are com-
patible with the hospital’s values and priorities. Generally, responsibilities include 
receiving requests (according to certain technical, medical, clinical, economic, and 
social aspects) from Healthcare Practitioners and/or decision makers in relation 
to the adoption of certain technology/intervention. This unit then aggregates all 
the available data (from primary and secondary sources), synchronize and analyze 
them appropriately, resulting in site-relevant clinical and economic final assess-
ments. disCussion: A single university (department) experience as a nucleus for 
HB HTA is centered on the three main interest of a university hospital: Research, 
Education and Clinical practice. It depends on the presence of: 1- A chemotherapy 
independent unit which can provide standardized regimens based on the HTA-based 
decisions, 2- Well-developed oncology electronic medical record to insure standard-
ized data collection and rapid communication between different departments, 3- an 
E-learning program, and 4- a clinical research unit.
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The Medicare Modernization Act of 2003 requires prescription drug plans to pro-
vide medication therapy management services to eligible Part D beneficiaries. 
In 2010, in an attempt to increase consistency among programs, the Centers for 
Medicare and Medicaid Services (CMS) expanded the regulatory requirements 
associated with medication therapy management (MTM). After evaluating the 
outcomes of MTM since its implementation in 2006, CMS concluded that the pro-
gram has fallen short of expectations. On implementation of MTM, CMS projected 
that 25 percent of Medicare beneficiaries would qualify for MTM based on the 
proposed eligibility criteria. In reality, the percent of MTM eligible beneficiaries 
has fallen far below that approximation. Among members who meet eligibility 
criteria, MTM completion rates remain around 20 percent, on average. CMS also 
notes that certain racial and ethnic disparities continue to exist in MTM eligibil-
ity. Specifically, African American and Hispanic beneficiaries are less likely to 
